-
公开(公告)号：US20200317776A1
公开(公告)日：2020-10-08
申请号：US16835140
申请日：2020-03-30
Applicant: Alector LLC
Inventor： Tina SCHWABE , Eric BROWN , Philip KONG , Ilaria TASSI , Seung-Joo LEE , Arnon ROSENTHAL , Robert PEJCHAL , Nels P. NIELSON
Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, antibodies, antibody fragments, etc., that specifically bind a TREM2 protein, e.g., a mammalian TREM2 or human TREM2, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
-
公开(公告)号：US20220348656A1
公开(公告)日：2022-11-03
申请号：US17836707
申请日：2022-06-09
Applicant: Alector LLC
Inventor： Tina SCHWABE , Michael KURNELLAS , Arnon ROSENTHAL , Robert PEJCHAL , Anthony B. COOPER
IPC: C07K16/28
Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, affinity-matured, humanized antibodies, antibody fragments, etc., that specifically bind a Sortilin protein, e.g., human Sortilin or mammalian Sortilin, and have improved and/or enhanced functional characteristics, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
-
公开(公告)号：US20180265586A1
公开(公告)日：2018-09-20
申请号：US15867609
申请日：2018-01-10
Applicant: ALECTOR LLC
Inventor： Arnon ROSENTHAL , Tina SCHWABE , Michael KURNELLAS , Robert PEJCHAL , Anthony B. COOPER
IPC: C07K16/28
CPC classification number: C07K16/2863 , A61K31/7088 , C07K16/286 , C07K2317/14 , C07K2317/21 , C07K2317/31 , C07K2317/34 , C07K2317/55 , C07K2317/56 , C07K2317/76 , C07K2317/92 , C07K2319/30 , C07K2319/32
Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind on or more epitopes within a Sortilin protein, e.g., human Sortilin or a mammalian Sortilin, and use of such compostions in preventing, reducing risk, or treating an individual in need thereof.
-
公开(公告)号：US20230312712A1
公开(公告)日：2023-10-05
申请号：US18174499
申请日：2023-02-24
Applicant: Alector LLC
Inventor： Tina SCHWABE , Eric BROWN , Philip KONG , Ilaria TASSI , Seung-Joo LEE , Arnon ROSENTHAL , Robert PEJCHAL , Nels P. NIELSON
CPC classification number: C07K16/2803 , A61P25/28 , C07K2317/71 , C07K2317/90 , C07K2317/75 , C07K2317/76 , A61K2039/505
Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, antibodies, antibody fragments, etc., that specifically bind a TREM2 protein, e.g., a mammalian TREM2 or human TREM2, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
-
公开(公告)号：US20200024348A1
公开(公告)日：2020-01-23
申请号：US16510773
申请日：2019-07-12
Applicant: Alector LLC
Inventor： Tina SCHWABE , Michael KURNELLAS , Arnon ROSENTHAL , Robert PEJCHAL , Anthony B. COOPER
IPC: C07K16/28
Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, affinity-matured, humanized antibodies, antibody fragments, etc., that specifically bind a Sortilin protein, e.g., human Sortilin or mammalian Sortilin, and have improved and/or enhanced functional characteristics, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
-
Patent Agency Ranking
公开(公告)号：US20230047941A1
公开(公告)日：2023-02-16
申请号：US17836644
申请日：2022-06-09
Applicant: Alector LLC
Inventor： Tina SCHWABE , Michael KURNELLAS , Arnon ROSENTHAL , Robert PEJCHAL , Anthony B. COOPER
IPC: C07K16/28
Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, affinity-matured, humanized antibodies, antibody fragments, etc., that specifically bind a Sortilin protein, e.g., human Sortilin or mammalian Sortilin, and have improved and/or enhanced functional characteristics, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
-
公开(公告)号：US20220251219A1
公开(公告)日：2022-08-11
申请号：US17721112
申请日：2022-04-14
Applicant: Alector LLC
Inventor： Arnon ROSENTHAL , Tina SCHWABE , Michael KURNELLAS , Robert PEJCHAL , Anthony B. COOPER
IPC: C07K16/28 , A61K31/7088
Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind on or more epitopes within a Sortilin protein, e.g., human Sortilin or a mammalian Sortilin, and use of such compostions in preventing, reducing risk, or treating an individual in need thereof.
-
公开(公告)号：US20220185899A1
公开(公告)日：2022-06-16
申请号：US17534291
申请日：2021-11-23
Applicant: Alector LLC
Inventor： Arnon ROSENTHAL , Tina SCHWABE , Michael KURNELLAS , Robert PEJCHAL , Anthony B. COOPER
IPC: C07K16/28 , A61K31/7088
Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind on or more epitopes within a Sortilin protein, e.g., human Sortilin or a mammalian Sortilin, and use of such compostions in preventing, reducing risk, or treating an individual in need thereof.
-
公开(公告)号：US20220162309A1
公开(公告)日：2022-05-26
申请号：US17581471
申请日：2022-01-21
Applicant: Alector LLC
Inventor： Patricia CULP , Helen LAM , Arnon ROSENTHAL , Seung-Joo LEE , Nels P. NIELSON , Robert PEJCHAL
Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind one or more epitopes within a CD33 protein, e.g., human CD33 or a mammalian CD33, and have improved and/or enhanced functional characteristics, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
-
公开(公告)号：US20210139581A1
公开(公告)日：2021-05-13
申请号：US16869315
申请日：2020-05-07
Applicant: ALECTOR LLC
Inventor： Patricia CULP , Helen LAM , Arnon ROSENTHAL , Seung-Joo LEE , Nels P. NIELSON , Robert PEJCHAL
Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind one or more epitopes within a CD33 protein, e.g., human CD33 or a mammalian CD33, and have improved and/or enhanced functional characteristics, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
-
-
-
-
-
-
-
-
-
Search Results
13
records
(took 0.019 seconds)
